| Activity‐Based Protein Profiling of Bile Salt Hydrolysis in the Human Gut Microbiome with Beta‐Lactam or Acrylamide‐Based Probes KR Brandvold, CJ Miller, RF Volk, BJ Killinger, C Whidbey, AT Wright ChemBioChem 22 (8), 1448-1455, 2021 | 13 | 2021 |
| Profiling How the Gut Microbiome Modulates Host Xenobiotic Metabolism in Response to Benzo[a]pyrene and 1-Nitropyrene Exposure WL Garcia, CJ Miller, GX Lomas, KA Gaither, KJ Tyrrell, JN Smith, ... Chemical Research in Toxicology 35 (4), 585-596, 2022 | 11 | 2022 |
| Simple analysis of primary and secondary bile salt hydrolysis in mouse and human gut microbiome samples by using Fluorogenic substrates A Sveistyte, T Gibbins, KJ Tyrrell, CJ Miller, MH Foley, AE Plymale, ... ChemBioChem 21 (24), 3539-3543, 2020 | 8 | 2020 |
| Probe-enabled approaches for function-dependent cell sorting and characterization of microbiome subpopulations AK Steiger, SJ Fansler, C Whidbey, CJ Miller, AT Wright Methods in enzymology 638, 89-107, 2020 | 3 | 2020 |
| Bile salt hydrolase profiling by fluorogenic probes in the human gut microbiome A Sveistyte, CJ Miller, KR Brandvold, AT Wright Methods in enzymology 664, 243-265, 2022 | 2 | 2022 |
| The global anaerobic metabolism regulator fnr is necessary for the degradation of food dyes and drugs by Escherichia coli LM Pieper, P Spanogiannopoulos, RF Volk, CJ Miller, AT Wright, ... Mbio 14 (5), e01573-23, 2023 | 1 | 2023 |
| EPS5. 02 Faecal microbiota changes in patients with cystic fibrosis with 6 months of elexacaftor/tezacaftor/ivacaftor: preliminary findings from the PROMISE study JT Duong, CE Pope, HS Hayden, C Miller, D Raftery, SJ Salipante, ... Journal of Cystic Fibrosis 22, S49, 2023 | 1 | 2023 |
| Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor JT Duong, CE Pope, HS Hayden, C Miller, SJ Salipante, SM Rowe, ... Journal of Cystic Fibrosis, 2024 | | 2024 |
| 528 Alterations in the fecal microbiota of patients with advanced cystic fibrosis–associated liver disease after 6 months of elexacaftortezacaftor-ivacaftor J Duong, C Pope, H Hayden, C Miller, S Salipante, S Rowe, G Solomon, ... Journal of Cystic Fibrosis 22, S278-S279, 2023 | | 2023 |
| Mo1885 FECAL MICROBIOTA CHANGES IN CHILDREN WITH CYSTIC FIBROSIS WITH 1 MONTH OF CFTR MODULATOR THERAPY ELEXACAFTOR/TEZACAFTOR/IVACAFTOR: PRELIMINARY FINDINGS FROM THE PROMISE … JT Duong, CE Pope, HS Hayden, C Miller, D Raftery, SJ Salipante, ... Gastroenterology 164 (6), S-929-S-930, 2023 | | 2023 |
| 213 Composition of fecal microbiota and bile acid abundances with 1 month of elexacaftor/tezacaftor/ivacaftor in pediatric patients with cystic fibrosis: Preliminary findings … J Duong, C Pope, H Hayden, C Miller, D Raftery, S Salipante, J Pittman, ... Journal of Cystic Fibrosis 21, S126-S127, 2022 | | 2022 |
Aaron T. WrightProfessor of Biomedical Sciences, Baylor UniversityVerified email at baylor.edu
